ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo)
ocrelizumab and hyaluronidase-ocsq is an FDA-licensed reference biologic from Genentech, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
Ocrevus Zunovo ocrelizumab and hyaluronidase-ocsq
Genentech, Inc.
- Approved
- Sep 13, 2024
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for ocrelizumab and hyaluronidase-ocsq, in chronological order.
Reference approval
Approval date of the reference ocrelizumab and hyaluronidase-ocsq product.
1 yr 9 mo ago
Frequently asked questions
Are there biosimilars approved for ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo)?
No 351(k) biosimilars or interchangeable biosimilars referencing ocrelizumab and hyaluronidase-ocsq are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.